The synthetic cyclic pentapeptide, ADH-1 (N-Ac-CHAVC-NH2) targets N-cadherins (it imitates the HAVD amino acid sequence of N-cadherin), increases cellular levels of E-cadherin, and has demonstrated efficacy in Phase I clinical trials against melanoma [373, 374]. The gene discussed is CDH2; the disease is melanoma.